Kornimate/medical-research-clean huggingface dataset:
sustained natural apophysial glides (snags) technique in non-specific neck pain patients

Conditions: Neck Pain

Summary: mechanical neck pain is defined for the absence of cervical spinal pathologies.with the snags mobile mobilization method, it reveals effective results in cases of limitation and pain in the cervical joints.although there are studies with the mulligan concept in the literature, studies examining the effects of the snags technique on non-specific neck pain are limited. the aim of this study is to investigate the effectiveness of the mulligan concept snags mobilization method applied in addition to the conventional physiotherapy program in individuals with nonspecific neck pain.

this study was conducted to investigate the effectiveness of mulligan concept cervical sustained natural apophysial glides (snags) mobilization method in addition to the conventional treatment program in patients with nonspecific neck pain. the study included 40 patients (18-50 years of age) with non-specific neck pain, radicular compression and loss of strength for at least 3 months, diagnosed by a specialist physician; patients with central nervous system disease, distal-peripheral nerve injuries patients with inflammatory joint disease, cervical spine fracture or surgery, patients with upper extremity surgery, cervical spine tumor and infection, cervical spine congenital anomaly and diabetes were not included in the study. 15 sessions were applied for 3 weeks, 5 days a week for 10 weeks, 10 minutes ultrasound, 20 minutes transcutaneous electrical nerve stimulation (tens) and hotpack application and mulligan mobilization in addition to physiotherapy programs. the patient was rested for 5 seconds between sets. the physiotherapy program was applied to the control group and the application session was completed. normal range of motion exercises were performed in both groups and given as home exercise.

Eligibility criteria:
inclusion criteria: * volunteer patients with non-specific neck pain lasting at least 3 months, * volunteer patients without radicular pressure, * volunteer patients with loss of strength, * volunteer patients diagnosed with non-specific neck pain by a specialist physician. exclusion criteria: * volunteer patients with central nervous system disease, * volunteer patients with distal-peripheral nerve injuries, * volunteer patients with inflammatory joint disease, * volunteer patients with cervical spine fracture or surgery, upper extremity surgery, * volunteer patients with vertebrobasilar artery stenosis, * volunteer patients with osteoporosis, * volunteer patients with cervical dislocation, * volunteer patients with cervical spine tumor and infection, * volunteer patients with congenital anomalies involving the spine, * volunteer patients with patients with diabetes.

Keywords: manual therapy neck pain snags sleep quality quality of life
a randomized, open-label, multi-center study to evaluate the efficacy and safety of intramuscular ziprasidone in patients with agitation

Conditions: Schizophrenia

Summary: this local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone im (intramuscular) in the chinese population with agitation in schizophrenia


Eligibility criteria:
inclusion criteria: * male or female chinese subjects aged 18-65 years (including 65) at screening. * subjects meeting the icd-10 (classification of mental and behavioral disorders) criteria for schizophrenia (f20.x). * subjects who are in acute phase of schizophrenia and are appropriate to receive intramuscular medication for at least 3 days exclusion criteria: * history of clinically significant physical illness especially myocardial infarction, non compensatory heart failure etc. * subjects receiving an investigational agent in the previous 3 months prior to screening. * use of antipsychotic agents within 12 hours or parenteral benzodiazepines within 4 hours prior to randomization and during the study.

Keywords: intramuscular ziprasidone, agitation, efficacy and safety
a study of mm-121 with paclitaxel in platinum resistant/ refractory advanced ovarian cancers

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer

Summary: to determine whether the combination of mm-121 plus paclitaxel is more effective than paclitaxel alone

this is a multicenter, open-label, randomized, phase ii study of mm-121 in patients with platinum resistant or refractory recurrent/advanced ovarian cancers. up to 210 patients will be randomized (2:1) to receive mm-121 plus paclitaxel or paclitaxel alone.

Eligibility criteria:
inclusion criteria: * locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer * received at least one prior platinum based chemotherapy regimen * platinum-resistant or refractory * eligible for weekly paclitaxel * adequate liver and kidney function * 18 years of age or above exclusion criteria: * evidence of any other active malignancy * history of severe allergic reactions to paclitaxel or other drugs formulated in cremophor®el

Keywords: ovarian cancer platinum-resistant platinum-refractory fallopian tube cancer peritoneal cancer paclitaxel erbb3 phase ii locally advanced/metastatic or recurrent
the clinical study of silicone hydrogel daily disposable stenfilcon a toric lens

Conditions: Astigmatism

Summary: the aim of this study is to evaluate the clinical performance of stenfilcon a toric lenses compared with etafilcon a toric lenses for astigmatism. if it is valuable, the clinical performance of stenfilcon a toric lens is also evaluated compared with habitual lenses.

this is a multi-sites, 50 subjects, randomized, open labeled, bilateral wear, dispensing study. participants will be randomized to wear first lens pair for two weeks, and then crossover to second lens pair for two weeks.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * is between 18 years of age and 42 years of age. * soft contact lens wearers who are not required to have presbyopic correction. * soft contact lens wearers without trouble. * soft contact lens wearers who have the correctable astigmatism by lenses used in this study in the both eyes. * has a prescribed scl (soft contact lens) power within the range of powers of the scl for astigmatism which is used in this study. * can achieve a corrected visual acuity of 1.0 or better. * can read and understand the study information document, and sign the participation consent form. * can visit the clinic at designated examination visits. * has received periodical examinations at an eye clinic within the past two years. exclusion criteria: a person will be excluded from the study if he/she: * has a systemic disease that may affect the ocular health. * is pregnant or lactating. * has received a systemic or local medication that may affect this study. * has an infectious eye disease. * has eye and systemic active allergic diseases that interferes with scl wear. * has an eye disease which is clinically judged to be severe such as corneal vascularization, limbal hyperemia, and corneal epithelium disorder * has a history of hard contact lens wear within 30 days. * is currently participating in another clinical research study. * has undergone refractive surgery.
3d laparoscopic adrenalectomies for adrenal tumors

Conditions: Adrenal Tumor; Adrenalectomy; Status

Summary: the main drawbacks of conventional 2d laparoscopy are limited depth perception and loss of spatial orientation. high-quality 3d laparoscopy systems might improve surgical outcomes for adrenalectomy.

over recent decades, technological advances such as improved video imaging (high-definition cameras), better instrumentation for dissection and hemostasis, articulating staplers, and optimized operating room lighting have added safety, efficacy, and precision to minimally invasive procedures. however, until recently, laparoscopy required surgeons to operate in a three-dimensional (3d) space with only two-dimensional (2d) images to guide their movements, resulting in a lack of depth perception and loss of spatial orientation that increased the risk of errors, fatigue, operative time, and operating room stress and made the technique difficult to learn. high-quality 3d laparoscopy was developed as an alternative to conventional 2d laparoscopy. several clinical trials and observational studies have compared surgical outcomes between 2d and 3d laparoscopic systems; however, few clinical studies have examined the usefulness of 3d laparoscopy systems for adrenalectomies.

Eligibility criteria:
inclusion criteria: * all adult patients (age ≥ 18 years) * patients diagnosed with adrenal masses (benign and malignant tumors) * underwent a unilateral 3d laparoscopic adrenalectomy from january 2013 to december 2033. exclusion criteria: * emergency surgery. * open adrenalectomy. * bilateral adrenalectomies (open or laparoscopy). * patients who underwent laparoscopic adrenalectomy together with another laparoscopic surgical procedure in the same intervention. * patients without complete follow-up for at least 30 days after hospital discharge.

Keywords: three-dimensional laparoscopy adrenal tumors 3d laparoscopic adrenalectomy
feasibility study - the place of surgical management by fatty autograft in patients with healed pelvic eschar. interest in secondary prevention.

Conditions: Eschar

Summary: autografting of fat cells is widely used in plastic surgery in breast reconstruction, burn scars, unsightly scars etc. it is known that the autografting of fat cells not only makes it possible to bring adipocytes, and thus to create a volume, but also promotes neo-angiogenesis by providing the growth factors which allows an improvement of the local cutaneous tissue. currently the investigators perform this action in their service on healed eschars, by analogy with burn scars that are also dystrophic, so as to improve cutaneous trophicity, and reduce the recurrence of eschars on these scars. however, the literature on the autografting of fat cells on eschars is limited.


Eligibility criteria:
inclusion criteria: * patient between 18 and 65 years old; * presenting a medullary, post-traumatic or congenital lesion, with consequent paraplegic sequelae; * with a history of eschar: * pelvic (ischiatic, trochanteric or sacral), * healed for at least 6 months, after surgical treatment or directed healing (scarring is defined by the absence of local care, ie no nursing care); * affiliated to a social security ; * written informed consent. exclusion criteria: * patient malnourished (albuminemia \<40g / l); * non-weaning or weaned tobacco addiction for less than 3 weeks (compared to the date of surgery); * contraindication to mri ; * protected person subject to legal protection (legal safeguards, guardianship, trusteeship), person deprived of liberty, * pregnant woman.

Keywords: healed pelvic eschar paraplegic patient fat autograft
efficacy and safety of focused shockwave therapy plus tadalafil vs tadalafil alone in patient with erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the goal of this trial is that using tadalafil plus low-intensity extracorporeal shockwave therapy (li-eswt) is more effective than using tadalafil alone in improving erection rigidity and sexual function. the efficacy of the combination of li-eswt and tadalafil has been confirmed by a number of studies, including in patients after radical prostatectomy. however, this method is still not a "first-line" method in young primary patients and its benefits in combination with drugs for these patients are not obvious. the investigators assume that the combination of tadalafil plus low-intensity extracorporeal shockwave therapy (li-eswt) will improve the subjective state of patients assessed by points of validated questionnaires and number of successful intercourse per week.

the aim of the study is to test the hypothesis that using tadalafil plus shockwave in primary patient with ed treatment in more effective in improving erection rigidity and sexual function, then using tadalafil alone.

Eligibility criteria:
inclusion criteria:• age 20 to 45; * married or have had a permanent sex partner for at least 3 months; * iief-5 questionnaire scores below 20 exclusion criteria: * history of previous use of pde-5 inhibitors or fswt; * patients with diabetes mellitus; * patients after the radical prostatectomy or major pelvic surgery; * patients with a confirmed neurological disease that may have caused the ed (multiple sclerosis, parkinson's disease, spinal cord injury); * patients with contraindications to the use of pde-5 inhibitors and/or fswt;
xnkq acupuncture compared to control interventions measured with eeg and fmri

Conditions: Stroke

Summary: the investigators will use eeg, structural mri, and resting-state functional connectivity mri to assess neuronal responses in 28 healthy subjects to different somatosensory stimulations.

to develop a better understanding of the cerebral response to a complex somatosensory intervention with xnkq acupuncture and to build a foundation for future studies with stroke patients our study aims to evaluate changes of brain activity and brain structure in healthy subjects after xnkq acupuncture in comparison to three control interventions. we will use eeg, structural mri, and resting-state functional connectivity mri to assess neuronal responses in 28 healthy subjects to a) strong manual needle-stimulation of the acupuncture points du26, pc6 and sp6 (xnkq acupuncture), b) insertion of needles on the acupuncture points du26, pc6 and sp6 without stimulation (control 1), c) strong manual needle stimulation of three non-acupuncture points (control 2), and d) insertion of needles on three non-acupuncture points without stimulation (control 3). with this, our study aims to create results which inform future studies in patients and might be helpful for the rehabilitation of deficits after stroke.

Eligibility criteria:
inclusion criteria: * healthy subjects (18 to 40 years of age) health status confirmed by a comprehensive neurological examination * right-handed (evaluated by "the edinburgh inventory") * informed consent * no acupuncture treatment in the last 12 months * no medical knowledge about acupuncture exclusion criteria: * history of neurological and/or psychiatric diseases * history of brain injury * cognitive handicap and severe speech disorder * alcohol or drug abuse * history of neurosurgical intervention * chronic disease (e.g., asthma, diabetes mellitus etc.) with regular use of medications * usage of acute medication * pregnancy (tested by urine pregnancy test before the measurement) or planned pregnancy * any contraindication for acupuncture (e.g., anti-coagulation therapy) * any exclusion criteria for mri scanning (metal implants (e.g. pacemaker), claustrophobia, etc.) * participation in another interventional trial.
side effects of newer antipsychotics in older adults

Conditions: Schizophrenia; Alzheimer's Disease; Dementia

Summary: this study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.

atypical antipsychotic medications introduced within the last decade have been used increasingly for the treatment of several types of psychotic disorders and severe behavioral disturbances in older individuals. this trend is primarily due to a decrease in side effects caused by the new medications, as compared to conventional neuroleptic medications. there is a lower risk for developing tardive dyskinesia and extrapyramidal symptoms, both of which are movement abnormalities, with new antipsychotic medications. however, there has been a growing concern that the newer medications can cause a different set of potentially serious adverse side effects. specifically, they may cause long-term metabolic, cardiovascular, and cerebrovascular effects, which may result in weight gain, diabetes, or stroke. this study will compare four atypical antipsychotic medications in terms of the risk of metabolic, cardiovascular, and cerebrovascular side effects that each presents in middle-aged and elderly individuals. participants in this open-label study will be randomly assigned to receive one of three atypical antipsychotic medications: aripiprazole; olanzapine; or risperidone. although assignment is random, a technique that may reflect the participant's own interests or the researcher's knowledge of relevant participant characteristics will be used to assign the participant to a medication. dosing will be determined by each participant's psychiatrist. participants will be followed for up to 5 years to assess the side effects of the study medications, with study visits at baseline, week 6, and every 3 months thereafter.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of a disease or disorder that requires treatment with an atypical antipsychotic medication exclusion criteria: * n/a

Keywords: antipsychotic diabetes hyperlipidemia stroke
elderly with hip fracture and perioperative hemoglobin and perfusion index levels

Conditions: Anemia; Delirium

Summary: the overall aim of the study is to investigate the time difference in the diagnosing of anemia among elderly with hip fracture, between measurements with standard blood samples and non-invasive sphb-measuring. another aim is to investigate the relationship between perfusion index and prolong perioperative anemia and the potential impact on perioperative complications.

immediately after admission and diagnosis of a hip fracture the patients will be monitored with masimo sphb. the patients will be continuously measured until the third day after surgery. the monitors hb and pi data but not the spo2% will be blinded to all participating healthcare personnel.the first three postopertive days the patiens will daily be examined to determined it they have developed delirium. all perioperativ complications in that period will be monitored.

Eligibility criteria:
inclusion criteria: * age ≥ 65 years * primary hip fracture requiring surgery * patients able to give informed consent * patients who are able to undergo the hospitals standardized fast track * perioperative care regimen for hip fracture including are pre operative placed epidural exclusion criteria: * patients who can not co-operate to have a sensor attach to the finger continuous for 4 days. * patients who has allergy to the bandage that is used to attach the sensor.

Keywords: postoperative anemia perfusion index
use of nebido® to assess tolerability and treatment outcomes in daily clinical practice

Conditions: Male; Hypogonadism

Summary: this is an observational study with a drug called nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. the benefit and safety of nebido have already been thoroughly evaluated through well controlled clinical trials. the main purpose of this observational study is to confirm the established safety profile of nebido in daily clinical practice.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * male hypogonadal patients eligible for long-term testosterone therapy who have newly been prescribed nebido® in accordance with the terms of the marketing authorization exclusion criteria: * patients presenting with contraindications as stated in the product information

Keywords: hypogonadism nebido testosterone observational study
predictive markers of the effects of opioid therapy

Conditions: Opioid Analgesic Treatment Response; Chronic Pain

Summary: the overall goal of the ability study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics. the investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced data analyses of data originating from pre-treatment eeg, qst and pain-related catastrophic thinking. the primary objective of this study is the identification of markers that can be used to individualize treatment recommendations, i.e. to reliably predict the response of pain to opioids. markers are selected among the most promising data and machine-learning methods are used for the prediction. this includes determining the associations between a battery of selected pre-treatment clinical predictive markers and the analgesic effect of opioid treatment in opioid naïve chronic pain patients, including indication and responder identification. the key secondary objectives are as follows: to investigate pre-treatment clinical predictive markers as predictors of opioid treatment efficacy and effectiveness in terms of the following: * pain intensity and unpleasantness * use of rescue analgesics * physical functioning * global improvement and satisfaction with treatment


Eligibility criteria:
inclusion criteria: * pain duration ≥ 3 months. * minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week). * maximum baseline pain intensity \< 9 on a 0-10 numerical rating scale (over the past week). * prescribed opioid treatment (atc: n02) * anticipated to stay on prescribed opioid treatment throughout the study, i.e. \>14 days. * anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. \>14 days. * subject may be male or female, age \>18 years old. * is willing and able to comply with study procedures as judged by the site investigator. * subject has voluntarily signed and dated the study-specific informed consent form, approved by an independent ethics committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. the informed consent form must be signed before any study-specific procedures are performed. exclusion criteria: * has a mental incapacity or language barriers precluding adequate understanding of study procedures. * is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition. * recently received opioids on a daily basis (within the last 10 weeks). * current alcohol or substance abuse, according to the site investigator's medical judgement. * is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.

Keywords: chronic pain opioid analgesics prediction study pharmaco-eeg